journal article·2017-04-25

Transformable Nanomaterials as an Artificial Extracellular Matrix for Inhibiting Tumor Invasion and Metastasis

Xiao-Xue Hu, Ping-Ping He, Guo-Bin Qi, Yu-Juan Gao, Yao-Xin Lin, Chao Yang, Pei-Pei Yang, Hongxun Hao, Lei Wang, Hao Wang

ACS Nano· Volume 11· Issue 4
Publisher page

Abstract

Tumor metastasis is one of the big challenges in cancer treatment and is often associated with high patient mortality. Until now, there is an agreement that tumor invasion and metastasis are related to degradation of extracellular matrix (ECM) by enzymes. Inspired by the formation of natural ECM and the in situ self-assembly strategy developed in our group, herein, we in situ constructed an artificial extracellular matrix (AECM) based on transformable Laminin (LN)-mimic peptide 1 (BP-KLVFFK-GGDGR-YIGSR) for inhibition of tumor invasion and metastasis. The peptide 1 was composed of three modules including (i) the hydrophobic bis-pyrene (BP) unit for forming and tracing nanoparticles; (ii) the KLVFF peptide motif that was inclined to form and stabilize fibrous structures through intermolecular hydrogen bonds; and (iii) the Y-type RGD-YIGSR motif, derived from LN conserved sequence, served as ligands to bind cancer cell surfaces. The peptide 1 formed nanoparticles (1-NPs) by the rapid precipitation method, owing to strong hydrophobic interactions of BP. Upon intravenous injection, 1-NPs effectively accumulated in the tumor site due to the enhanced permeability and retention (EPR) effect and/or targeting capability of RGD-YIGSR. The accumulated 1-NPs simultaneously transformed into nanofibers (1-NFs) around the solid tumor and further entwined to form AECM upon binding to receptors on the tumor cell surfaces. The AECM stably existed in the primary tumor site over 72 h, which consequently resulted in efficiently inhibiting the lung metastasis in breast and melanoma tumor models. The inhibition rates in two tumor models were 82.3% and 50.0%, respectively. This in vivo self-assembly strategy could be widely utilized to design effective drug-free biomaterials for inhibiting the tumor invasion and metastasis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Supramolecular Self-Assembly in Materials · Nanoplatforms for cancer theranostics · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Engineering Research Center of Industrial Crystallization Technology, State Key Laboratory of Chemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, P. R. China

CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST) No. 11 Beiyitiao, Zhongguancun, Beijing 100190, China

Funding

Natural Science Foundation of Tianjin City · Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China

References (41)

Show source-provided references
1. 10.1016/j.cell.2006.11.00110.1016/j.cell.2006.11.001 ↗
2. 10.1038/nrc372610.1038/nrc3726 ↗
3. 10.1038/nrc188610.1038/nrc1886 ↗
4. 10.1016/j.biomaterials.2014.01.01810.1016/j.biomaterials.2014.01.018 ↗
5. 10.1002/smll.20160113710.1002/smll.201601137 ↗
6. 10.1002/adma.20140182510.1002/adma.201401825 ↗
7. 10.1038/8464310.1038/84643 ↗
8. 10.1016/S0962-8924(01)02122-510.1016/S0962-8924(01)02122-5 ↗
9. 10.1039/C4CS00133H10.1039/C4CS00133H ↗
10. 10.1002/adma.20130520610.1002/adma.201305206 ↗
11. 10.1002/smll.20150318810.1002/smll.201503188 ↗
12. 10.1083/jcb.20110214710.1083/jcb.201102147 ↗
13. 10.1038/nrc72710.1038/nrc727 ↗
14. 10.1002/jcp.2528910.1002/jcp.25289 ↗
15. 10.1038/nnano.2010.24610.1038/nnano.2010.246 ↗
16. 10.1038/nbt105510.1038/nbt1055 ↗
17. 10.1039/C5CC05395A10.1039/C5CC05395A ↗
18. 10.1039/C6NR03580A10.1039/C6NR03580A ↗
19. 10.1002/adma.20150259810.1002/adma.201502598 ↗
20. 10.1002/adma.20160586910.1002/adma.201605869 ↗
21. 10.1002/adma.20150343710.1002/adma.201503437 ↗
22. 10.1016/j.biomaterials.2004.02.01210.1016/j.biomaterials.2004.02.012 ↗
23. 10.1038/nrc234510.1038/nrc2345 ↗
24. 10.1038/nrc274810.1038/nrc2748 ↗
25. 10.1038/4344110.1038/43441 ↗
26. 10.1021/bm500385n10.1021/bm500385n ↗
27. 10.1021/mp300273310.1021/mp3002733 ↗
28. 10.1021/acs.molpharmaceut.5b0000710.1021/acs.molpharmaceut.5b00007 ↗
29. 10.1039/C6TB00097E10.1039/C6TB00097E ↗
30. 10.1021/mp400026y10.1021/mp400026y ↗
31. 10.1021/mp300452g10.1021/mp300452g ↗
32. 10.1021/jp409557g10.1021/jp409557g ↗
33. 10.1002/adma.20130120210.1002/adma.201301202 ↗
34. 10.1016/j.biomaterials.2013.10.07210.1016/j.biomaterials.2013.10.072 ↗
35. Somasundaran P. · 2006
36. 10.1038/nmat447410.1038/nmat4474 ↗
37. 10.1177/108705710934176610.1177/1087057109341766 ↗
38. 10.1016/j.biomaterials.2014.05.09410.1016/j.biomaterials.2014.05.094 ↗
39. 10.1021/ja408182p10.1021/ja408182p ↗
40. 10.1016/j.biomaterials.2015.01.04910.1016/j.biomaterials.2015.01.049 ↗
41. 10.1021/mp200083n10.1021/mp200083n ↗